Moderna, Inc.
NASDAQ:MRNABiotechnology
+$2.48 today
- Market cap
- $79.63B
- Beta
- 1.03
- P/E (TTM)
- -7.9
- EPS (TTM)
- -$8.09
Volume 6.91M
Average 6.53M
MRNA Net Income
Bottom-line profit after all expenses, interest, and taxes.
Moderna, Inc.NASDAQ: MRNA
Net Income · Q3 FY2026 · quarter ended Sep 2026
Net income turns positive
Q3 FY2026 net income was $162M, compared with -$200M a year earlier. Trailing-twelve-month net income was -$2.79B.
Context
- Net income amounted to 145.2% of revenue in FY2025, up 33.8 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 14 analysts of -$2.89B (-2.4%) for the fiscal year ending Dec 2026, a slowdown from the +20.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $162M+120.7% QoQ
- Last fiscal yearDec 2025
- -$2.82B+20.8% YoY
- LTMSep 2026
- -$2.79B+10.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +181.0% | -8.4% | -189.4 pp |
| 1 year | +20.8% | -2.4% | -23.2 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (2.82B) USD
- Year-over-year change
- +20.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.82B) | +20.8% |
| FY2024 | 2024-12-31 | (3.56B) | +24.5% |
| FY2023 | 2023-12-31 | (4.71B) | -156.4% |
| FY2022 | 2022-12-31 | 8.36B | -31.5% |
| FY2021 | 2021-12-31 | 12.2B | — |
Net Income vs competitors
How MRNA compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +10.5% is the 4th highest of 10, against a peer median of -59.7%.
- Net income amounts to 110.5% of revenue for MRNA, versus a peer median of 64.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | £4.82B GBP | +40.8% | -27.4% | 14.5% | |
| LTM Jun 2026 | $4.33B USD | -59.7% | -37.2% | 6.8% | |
| LTM Mar 2026 | -$78.67M USD | -15.4% | — | 173.5% | |
| LTM Mar 2026 | -$84.93M USD | +12.0% | — | — | |
| LTM Mar 2026 | -$87.84M USD | -118.3% | — | 14.7% | |
| LTM Mar 2026 | -€138.03M EUR | -71.7% | — | 88.3% | |
| LTM Mar 2026 | -$442.72M USD | +23.4% | — | 676.0% | |
| LTM Jun 2026 | -$1.06B USD | -94.4% | — | — | |
| LTM Jun 2026 | -€1.69B EUR | -390.8% | — | 64.0% | |
| LTM Sep 2026 | -$2.79B USD | +10.5% | — | 110.5% | |
| Peer median (excluding MRNA) | — | -59.7% | -32.3% | 64.0% | |
Competitors are the stored peer set for MRNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 17.74B | 18.88B | 6.85B | 3.2B | 1.94B |
| Cost of Revenue | 2.62B | 5.42B | 4.69B | 1.46B | 868M |
| Gross Profit | 15.12B | 13.46B | 2.16B | 1.74B | 1.08B |
| Gross Margin | 85.2% | 71.3% | 31.5% | 54.2% | 55.3% |
| Research & Development | 1.99B | 3.3B | 4.85B | 4.54B | 3.13B |
| Selling, General & Admin | 567M | 1.13B | 1.55B | 1.17B | 1.02B |
| Operating Expenses | 1.82B | 4.04B | 6.39B | 5.68B | 4.15B |
| Depreciation & Amortization | 232M | 348M | 621M | 189M | 215M |
| EBITDA | 13.54B | 9.95B | (3.28B) | (3.39B) | (2.55B) |
| EBITDA Margin | 76.3% | 52.7% | -47.9% | -106.1% | -131.3% |
| Operating Income | 13.3B | 9.42B | (4.24B) | (3.95B) | (3.07B) |
| Operating Margin | 75.0% | 49.9% | -61.9% | -123.3% | -158.1% |
| Interest Income | 18M | 200M | 421M | 425M | 314M |
| Interest Expense | 18M | 29M | 38M | 24M | 10M |
| Other Income / Expenses | (11M) | 155M | 297M | 338M | 306M |
| Income Before Tax | 13.29B | 9.58B | (3.94B) | (3.61B) | (2.77B) |
| Pre-Tax Margin | 74.9% | 50.7% | -57.6% | -112.8% | -142.4% |
| Income Tax Expense | 1.08B | 1.21B | 772M | (46M) | 54M |
| Net Income | 12.2B | 8.36B | (4.71B) | (3.56B) | (2.82B) |
| Net Margin | 68.8% | 44.3% | -68.8% | -111.3% | -145.2% |
| EPS (Basic) | 30.31 | 21.26 | (12.34) | (9.27) | (7.26) |
| EPS (Diluted) | 28.29 | 20.10 | (12.34) | (9.27) | (7.26) |
| Weighted Avg Shares | 403M | 394M | 382M | 384M | 389M |
| Weighted Avg Shares (Diluted) | 431M | 416M | 382M | 384M | 389M |
Moderna, Inc.
NASDAQ:MRNA
Intrinsic Alpha fair value
Locked
Current Price
$196.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.